LivaNova (LIVN)


Market Price (11/22/2026): $90.93 | Market Cap: $5.0 BilSector: Health Care | Industry: Health Care Equipment

LivaNova (LIVN)


Market Price (11/22/2026): $90.93
Market Cap: $5.0 Bil
Sector: Health Care
Industry: Health Care Equipment

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 16%

Low stock price volatility
Vol 12M is 39%

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Chronic Disease Management, and Targeted Therapies.

Trading close to highs
Dist 52W High is -4.0%, Dist 3Y High is -4.0%

Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.42, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12%

Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 33x

Key risks
LIVN key risks include [1] a slow growth rate in its neuromodulation segment and [2] a significant $363 million liability ruling in Italy and ongoing SNIA litigation.

0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 16%
1 Low stock price volatility
Vol 12M is 39%
2 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Chronic Disease Management, and Targeted Therapies.
3 Trading close to highs
Dist 52W High is -4.0%, Dist 3Y High is -4.0%
4 Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.42, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12%
5 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 33x
6 Key risks
LIVN key risks include [1] a slow growth rate in its neuromodulation segment and [2] a significant $363 million liability ruling in Italy and ongoing SNIA litigation.

LIVN in ETFs

Weight = LIVN's share of each fund

ITOT0.01%
IWM0.18%
IJH0.14%
AVUV0.45%
MDYG0.30%
IJK0.29%
IWN0.27%
MDY0.15%
+12 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/20/2026

Nov 4: up 17.9% on its earnings report (S&P 500 up 1.7%)
The stock gained after LivaNova reported third-quarter 2026 results, beating earnings and revenue estimates and raising full-year guidance.

Up 64.2% from its May 5 low to Nov 18, down 4.0% since (S&P 500 up 1.4%)
The stock's run was primarily driven by positive reactions to quarterly earnings reports, which surpassed estimates and raised full-year guidance. Key gains followed first-quarter 2026 results on May 6-7, 2026, and third-quarter 2026 results on November 4, 2026.

Show more
Prices as of 11/20/2026

Nov 4: up 17.9% on its earnings report (S&P 500 up 1.7%)
The stock gained after LivaNova reported third-quarter 2026 results, beating earnings and revenue estimates and raising full-year guidance.

Up 64.2% from its May 5 low to Nov 18, down 4.0% since (S&P 500 up 1.4%)
The stock's run was primarily driven by positive reactions to quarterly earnings reports, which surpassed estimates and raised full-year guidance. Key gains followed first-quarter 2026 results on May 6-7, 2026, and third-quarter 2026 results on November 4, 2026.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 13.2% change in LIVN stock from 7/31/2026 to 11/21/2026 was primarily driven by a 74.1% change in the company's Net Income Margin (%).
(LTM values as of)731202611212026Change
Stock Price ($)80.1490.7313.2%
Change Contribution By: 
Total Revenues ($ Mil)1,4331,5075.1%
Net Income Margin (%)7.5%13.0%74.1%
P/E Multiple40.925.5-37.7%
Shares Outstanding (Mil)5555-0.7%
Cumulative Contribution13.2%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/21/2026
ReturnCorrelation
LIVN13.2% 
Market (SPY)-7.4%38.2%
Sector (XLV)9.5%39.8%

Fundamental Drivers

The 51.0% change in LIVN stock from 4/30/2026 to 11/21/2026 was primarily driven by a 40.3% change in the company's P/S Multiple.
(LTM values as of)430202611212026Change
Stock Price ($)60.1090.7351.0%
Change Contribution By: 
Total Revenues ($ Mil)1,3881,5078.6%
P/S Multiple2.43.340.3%
Shares Outstanding (Mil)5555-0.9%
Cumulative Contribution51.0%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/21/2026
ReturnCorrelation
LIVN51.0% 
Market (SPY)-3.5%30.7%
Sector (XLV)22.4%34.8%

Fundamental Drivers

The 72.4% change in LIVN stock from 10/31/2025 to 11/21/2026 was primarily driven by a 51.2% change in the company's P/S Multiple.
(LTM values as of)1031202511212026Change
Stock Price ($)52.6390.7372.4%
Change Contribution By: 
Total Revenues ($ Mil)1,3091,50715.1%
P/S Multiple2.23.351.2%
Shares Outstanding (Mil)5555-0.9%
Cumulative Contribution72.4%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/21/2026
ReturnCorrelation
LIVN72.4% 
Market (SPY)2.2%36.0%
Sector (XLV)24.9%38.5%

Fundamental Drivers

The 85.0% change in LIVN stock from 10/31/2023 to 11/21/2026 was primarily driven by a 38.9% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202311212026Change
Stock Price ($)49.0590.7385.0%
Change Contribution By: 
Total Revenues ($ Mil)1,0851,50738.9%
P/S Multiple2.43.336.3%
Shares Outstanding (Mil)5455-2.3%
Cumulative Contribution85.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/21/2026
ReturnCorrelation
LIVN85.0% 
Market (SPY)71.0%35.6%
Sector (XLV)49.6%33.4%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
LIVN Return32%-36%-7%-10%33%47%37%
Peers Return21%-13%4%10%2%-17%0%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
LIVN Win Rate50%42%42%50%50%55% 
Peers Win Rate55%47%52%63%52%45% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
LIVN Max Drawdown-17%-50%-30%-32%-33%-19% 
Peers Max Drawdown-22%-36%-30%-25%-24%-39% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, BSX, ABT, EW, INSP.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/20/2026 (YTD)

How Low Can It Go

EventLIVNS&P 500
2025 US Tariff Shock
  % Loss-28.8%-18.8%
  % Gain to Breakeven40.4%23.1%
  Time to Breakeven63 days79 days
2024 Yen Carry Trade Unwind
  % Loss-13.2%-7.8%
  % Gain to Breakeven15.2%8.5%
  Time to Breakeven17 days18 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-18.9%-9.5%
  % Gain to Breakeven23.3%10.5%
  Time to Breakeven78 days24 days
2023 SVB Regional Banking Crisis
  % Loss-25.6%-6.7%
  % Gain to Breakeven34.4%7.1%
  Time to Breakeven135 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-49.6%-24.5%
  % Gain to Breakeven98.2%32.4%
  Time to Breakeven1482 days427 days
2020 COVID-19 Crash
  % Loss-51.1%-33.7%
  % Gain to Breakeven104.5%50.9%
  Time to Breakeven322 days140 days

Compare to MDT, BSX, ABT, EW, INSP

In The Past

LivaNova's stock fell -28.8% during the 2025 US Tariff Shock. Such a loss loss requires a 40.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventLIVNS&P 500
2025 US Tariff Shock
  % Loss-28.8%-18.8%
  % Gain to Breakeven40.4%23.1%
  Time to Breakeven63 days79 days
2023 SVB Regional Banking Crisis
  % Loss-25.6%-6.7%
  % Gain to Breakeven34.4%7.1%
  Time to Breakeven135 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-49.6%-24.5%
  % Gain to Breakeven98.2%32.4%
  Time to Breakeven1482 days427 days
2020 COVID-19 Crash
  % Loss-51.1%-33.7%
  % Gain to Breakeven104.5%50.9%
  Time to Breakeven322 days140 days
2016-2017 Trump Reflation Bond Selloff
  % Loss-32.2%-3.7%
  % Gain to Breakeven47.4%3.9%
  Time to Breakeven211 days6 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-26.0%-12.2%
  % Gain to Breakeven35.1%13.9%
  Time to Breakeven610 days62 days
2014-2016 Oil Price Collapse
  % Loss-26.0%-6.8%
  % Gain to Breakeven35.1%7.3%
  Time to Breakeven610 days15 days

Compare to MDT, BSX, ABT, EW, INSP

In The Past

LivaNova's stock fell -28.8% during the 2025 US Tariff Shock. Such a loss loss requires a 40.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About LivaNova (LIVN)

LivaNova PLC (LIVN) is a global medical device company specializing in the design, development, manufacture, and sale of therapeutic solutions. The company operates through three core segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support, addressing critical needs in various medical fields.

The company's Cardiopulmonary segment offers products essential for open-heart surgery, including oxygenators, heart-lung machines, and autotransfusion systems. The Advanced Circulatory Support segment provides temporary life support solutions, such as cardiopulmonary and respiratory support systems. These offerings primarily serve perfusionists and hospitals for complex surgical and critical care scenarios.

LivaNova's Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS). This therapy is utilized for treating drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. The company's customer base includes neurologists, neurosurgeons, and other physicians, as well as hospitals, medical institutions, and healthcare providers worldwide.

AI Analysis | Feedback

Here are 1-2 brief analogies to describe LivaNova (LIVN):
  1. Like Medtronic, but specializing in implantable vagus nerve stimulation for neurological and mental health conditions.
  2. Similar to Getinge, but focused on critical heart-lung machines and temporary life support systems.

AI Analysis | Feedback

  • Cardiopulmonary Products: Includes oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, and connect for cardiopulmonary support.
  • VNS Therapy System: An implantable device delivering vagus nerve stimulation (VNS) therapy for drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea.
  • Advanced Circulatory Support Products: These temporary life support products provide cardiopulmonary and respiratory support solutions.

AI Analysis | Feedback

LivaNova (LIVN) primarily sells its therapeutic solutions to healthcare institutions and medical professionals. The company does not appear to have major customer companies that are publicly traded in the sense of supplying components or products for their own resale or integration into their own consumer offerings.

Based on the company description, the major categories of customers LivaNova serves are:

  1. Hospitals and Medical Institutions: These include hospitals, clinics, and other medical facilities where LivaNova's cardiopulmonary, neuromodulation, and advanced circulatory support products are utilized for patient care.
  2. Healthcare Providers and Medical Professionals: This category encompasses the individual professionals who directly use or decide on the use of LivaNova's products. Specifically mentioned are perfusionists, neurologists, neurosurgeons, and other physicians.

AI Analysis | Feedback

null

AI Analysis | Feedback

Vladimir Makatsaria, Chief Executive Officer

Vladimir Makatsaria was appointed Chief Executive Officer of LivaNova on March 1, 2024. He previously spent 27 years at Johnson & Johnson (J&J) in various global executive leadership roles. His most recent position at J&J MedTech was Company Group Chairman, where he led Ethicon, a global surgical technologies business. His tenure at J&J also included leadership roles for J&J China, J&J MedTech APAC, and Ethicon EMEA. He served as Chairman of the Board of the Asia Pacific Medical Technology Association and as an Advisory Board Member to Singapore Management University. Mr. Makatsaria holds a bachelor's degree in physiology, an MBA, and a master's in healthcare administration, all from the University of Minnesota.

Alex Shvartsburg, Chief Financial Officer

Alex Shvartsburg is the Chief Financial Officer of LivaNova, responsible for finance, accounting, and investor relations. He previously served as interim Chief Financial Officer of LivaNova from November 2020 to July 2021. Before his appointment as CFO, he led LivaNova's Corporate Financial Planning and Analysis group and was the International Region CFO. Prior to joining LivaNova in 2017, Mr. Shvartsburg was the CFO and Chief Operating Officer of Caligor, a private equity-backed clinical services organization, where he managed finance, operations, human resources, and information technology. His earlier career included finance leadership roles such as CFO of the Genetic Sciences division at Thermo Fisher Scientific, Senior Finance Director M&A at Life Technologies, and over 20 years in various finance roles at Johnson & Johnson. Mr. Shvartsburg holds a Bachelor of Science degree in Accounting from Drexel University and an MBA from LaSalle University, and is a Certified Management Accountant.

Ahmet Tezel, Chief Innovation Officer

Ahmet Tezel joined LivaNova in May 2024 as Chief Innovation Officer, overseeing innovation for the company’s core businesses, obstructive sleep apnea (OSA), and depression programs. He is also responsible for Enterprise Quality. With a 20-year track record, Dr. Tezel has guided teams in developing market-leading technologies across various medical fields. Before LivaNova, he was Company Group Chairman at Johnson & Johnson MedTech, where he led Global R&D and Innovation teams.

Philip Kowalczyk, Chief Strategy and Corporate Development Officer

Philip Kowalczyk became LivaNova’s Chief Strategy and Corporate Development Officer in August 2024. He brings extensive experience in creating and executing strategies within the medtech industry. Prior to LivaNova, he spent 16 years at Johnson & Johnson (J&J) Medtech, serving on the global leadership teams for both the Vision and Ethicon subsidiaries. His roles at J&J included Vice President of Business Development-Vision and Head of Asia Pacific Strategy and Business Development in Singapore, where he managed regional inorganic initiatives and integrated global acquisitions. For Ethicon, he served as Head of Global Strategy, Insights & Pricing, and Business Development Director. Mr. Kowalczyk holds a bachelor's degree in politics from Princeton University and an MBA in finance and strategy from The University of Michigan's Stephen M. Ross School of Business.

Natalia Kozmina, Chief Human Resources Officer

Natalia Kozmina joined LivaNova in January 2025 as Chief Human Resources Officer (CHRO). She has over 25 years of leadership experience in the medtech and life sciences sectors, having worked in Fortune 100 and FTSE 100 companies. Before her role at LivaNova, Ms. Kozmina was Executive Vice President, CHRO and ESG Stewardship of Convatec Group PLC. She also held senior human resources leadership positions at Iron Mountain and Smiths Group PLC.

AI Analysis | Feedback

The key risks to LivaNova's business include intense competition within its concentrated product portfolio, the challenges of navigating a stringent and evolving regulatory landscape, and significant ongoing litigation resulting in substantial financial liabilities.

  1. Intense Competition and Product Portfolio Concentration: LivaNova derives a substantial portion of its revenue from its Vagus Nerve Stimulation (VNS) therapy and heart-lung machines, with these two lines accounting for approximately 68% of product sales in 2024. This concentration makes the company particularly vulnerable to intense competition from larger medical device companies such as Medtronic and Abbott, who possess broader product portfolios and greater purchasing leverage with hospital groups. Such competition can lead to pricing pressure, potential loss of market share, and necessitates continuous investment in research and development to maintain innovation and provide robust clinical evidence.
  2. Regulatory Hurdles and Increasing Compliance Costs: As a global medical device company, LivaNova operates under stringent and continuously evolving regulatory oversight in the U.S. and internationally. The company faces increasing compliance costs, particularly related to regulations like the European Medical Device Regulation (MDR) and other product-related requirements. These regulatory hurdles can lead to delays in product approvals, increased operational complexities, and impact LivaNova's ability to effectively market and distribute its therapeutic solutions.
  3. Significant Litigation and Financial Liabilities: LivaNova is exposed to substantial legal challenges, most notably the ongoing SNIA litigation concerning environmental liabilities associated with its former parent company. A ruling in the first half of 2025 indicated a financial liability of approximately $363 million. This significant legal burden can strain the company's cash flow and impact its overall financial performance and profitability.

AI Analysis | Feedback

null

AI Analysis | Feedback

LivaNova PLC operates in several key medical device markets, with its primary products and services addressing cardiopulmonary, neuromodulation, and advanced circulatory support needs. The addressable markets for these solutions are substantial globally and within key regions.

Cardiopulmonary and Advanced Circulatory Support

LivaNova's Cardiopulmonary and Advanced Circulatory Support segments are involved in products such as heart-lung machines, oxygenators, and temporary life support systems like Extracorporeal Membrane Oxygenation (ECMO) devices.

  • The global heart-lung machine market was valued at approximately USD 2.51 billion in 2025 and is estimated to reach USD 4.54 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.86%. Another estimate places the global heart-lung machine market at USD 2.3 billion in 2023, projected to reach USD 4.5 billion by 2033, growing at a CAGR of 6.7%. The U.S. market for heart-lung machines was valued at USD 878.36 million in 2024 and is projected to reach USD 934.84 million in 2025.
  • The global extracorporeal life support (ECLS) devices market was estimated at USD 2.5 billion in 2024 and is projected to reach USD 5.1 billion by 2034, registering a CAGR of 7.5%. Similarly, the global extracorporeal membrane oxygenation (ECMO) market size was around USD 582.63 million in 2024 and is predicted to grow to approximately USD 904.81 million by 2034. North America held the largest share of the extracorporeal life support devices market in 2024. The USA veno-venous extracorporeal life support (VV ECLS) devices market alone is estimated at USD 532.7 million in 2025 and is anticipated to reach USD 1.0 billion by 2035.
  • More broadly, the global cardiopulmonary products market size was estimated to be USD 472.50 million in 2023 and is expected to reach USD 884.92 million by 2033.

Neuromodulation - VNS Therapy System

LivaNova's Neuromodulation segment primarily focuses on its VNS Therapy System for treating drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea.

  • The global vagus nerve stimulation (VNS) market size is valued at USD 575.81 million in 2025 and is estimated to reach USD 974.30 million by 2034, growing at a CAGR of 6.06%. North America holds the largest share of the global VNS market. The U.S. VNS market was valued at USD 296.38 million in 2025.
  • For drug-resistant epilepsy, a key application for VNS therapy, the VNS segment held around 22% of the global refractory epilepsy market in 2024, representing an estimated market size of approximately USD 1.47 billion. The broader global drug-resistant epilepsy treatment market was valued at USD 4,634.9 million in 2024 and is projected to reach USD 9,472.6 million by 2035. The top 7 major markets (US, EU4, UK, and Japan) for drug-resistant epilepsy were valued at USD 3.8 billion in 2024 and are expected to reach USD 6.4 billion by 2035.
  • For difficult-to-treat depression, also known as treatment-resistant depression (TRD), the global TRD treatment market is projected to reach a valuation of USD 2.69 billion in 2025, with expectations to surge to USD 5.0 billion by 2035. Another source states the global treatment-resistant depression market is expected to grow from USD 2.16 billion in 2025 to USD 3.36 billion by 2031. North America leads this market.
  • For obstructive sleep apnea, while specific market size for VNS therapy for OSA was not readily available, the broader global sleep apnea devices market was estimated at USD 7.11 billion in 2025 and is predicted to increase to USD 13.18 billion by 2034. North America dominates the sleep apnea devices market.

VITARIA System for Heart Failure

LivaNova is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. Information on the addressable market size for VNS specifically for heart failure is not currently available in the provided search results.

AI Analysis | Feedback

LivaNova (LIVN) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market expansions:

  • Entry and Scaling in the Obstructive Sleep Apnea (OSA) Market: LivaNova is strategically entering the obstructive sleep apnea (OSA) market with its proximal hypoglossal nerve stimulation (p-HGNS) technology, specifically the aura6000 System. A Premarket Approval (PMA) submission to the FDA for this technology was targeted for the first half of 2025, with an independent commercial launch anticipated in the second half of 2027. This initiative is projected to generate significant revenue, with forecasts ranging from $200 million to $400 million by 2030.
  • Continued Growth in the Core Cardiopulmonary Business: The Cardiopulmonary segment remains a strong foundation for LivaNova's growth. This includes sustained demand for consumables and the continued success and expansion of the Essenz Perfusion System. The Essenz system is a significant driver, with its launch in new markets such as China contributing to revenue growth. The company anticipates Cardiopulmonary revenue to grow between 7% and 8% in 2026.
  • Expansion and Reimbursement Improvements in Neuromodulation for Epilepsy: The Neuromodulation segment, particularly VNS Therapy for drug-resistant epilepsy, is expected to continue its growth trajectory. Key drivers include increased provider reimbursement from the U.S. Centers for Medicare & Medicaid Services (CMS) for VNS Therapy procedures, effective January 1, 2026, which saw hospital outpatient payments rise approximately 48% for new patient implants and 47% for end-of-service procedures compared to 2025 rates. Additionally, new product launches like a connected care platform in 2026 and a Bluetooth-enabled implantable pulse generator in 2027 are expected to contribute to growth.
  • Leveraging Innovation and New Product Introductions: Beyond specific market entries, LivaNova is focused on continuous innovation across its portfolio. This includes developing a new generation of oxygenators for the cardiopulmonary segment (planned for 2028) and enhancing its neuromodulation capabilities with new technologies like the cloud-based digital health platform which received FDA approval.

AI Analysis | Feedback

Share Repurchases

  • LivaNova had a 3-year average share buyback ratio of -0.7, indicating net share issuance rather than repurchases over the period.

Share Issuance

  • In March 2024, LivaNova priced a private offering of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029, with expected net proceeds of approximately $289.3 million. These notes are convertible into ordinary shares under certain conditions.
  • The number of ordinary shares outstanding was approximately 53.9 million as of February 23, 2024, and is expected to be approximately 56 million for the full-year 2026.

Outbound Investments

  • On June 1, 2021, LivaNova divested its Heart Valve business.

Capital Expenditures

  • Capital expenditures were $25 million in 2021, $27 million in 2022, $35 million in 2023, and $47 million in 2024.
  • For 2025, capital expenditures were approximately $71 million.
  • LivaNova is investing in its core businesses and a transformational pipeline, including scaling Obstructive Sleep Apnea (OSA) and developing a next-generation oxygenator (estimated launch 2028), a connected care platform (estimated launch 2026), and a Bluetooth-enabled implantable pulse generator (estimated launch 2027).

Better Bets vs. LivaNova (LIVN)

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

LIVNMDTBSXABTEWINSPMedian
NameLivaNova MedtronicBoston S.Abbott L.Edwards .Inspire . 
Mkt Price90.93100.0042.13103.31101.8655.1095.47
Mkt Cap5.0128.061.0179.258.71.659.9
Rev LTM1,50737,54121,06948,2296,67588113,872
Op Inc LTM1627,1474,3386,6471,922163,130
FCF LTM1296,1321,5166,7571,424981,470
FCF 3Y Avg1435,5272,3256,720905781,615
CFO LTM2388,0354,2348,8551,7171352,975
CFO 3Y Avg2167,3603,9328,9011,1801162,556

Growth & Margins

LIVNMDTBSXABTEWINSPMedian
NameLivaNova MedtronicBoston S.Abbott L.Edwards .Inspire . 
Rev Chg LTM11.7%9.8%8.9%10.0%13.4%-0.2%9.9%
Rev Chg 3Y Avg10.5%6.0%15.4%6.5%14.7%16.4%12.6%
Rev Chg Q9.9%13.7%1.4%14.5%10.5%-7.9%10.2%
QoQ Delta Rev Chg LTM2.4%3.2%0.3%3.5%2.5%-2.0%2.4%
Op Inc Chg LTM-16.4%7.5%16.6%-13.8%18.7%-57.1%-3.1%
Op Inc Chg 3Y Avg90.3%6.3%23.2%4.3%11.7%80.7%17.5%
Op Mgn LTM10.7%19.0%20.6%13.8%28.8%1.8%16.4%
Op Mgn 3Y Avg10.9%18.5%19.2%15.9%28.1%2.6%17.2%
QoQ Delta Op Mgn LTM-2.0%0.3%-0.4%-2.0%0.7%-4.2%-1.2%
CFO/Rev LTM15.8%21.4%20.1%18.4%25.7%15.3%19.2%
CFO/Rev 3Y Avg15.7%21.2%20.8%20.1%19.4%13.6%19.7%
FCF/Rev LTM8.6%16.3%7.2%14.0%21.3%11.1%12.6%
FCF/Rev 3Y Avg10.5%15.9%12.5%15.2%14.7%9.1%13.6%

Valuation

LIVNMDTBSXABTEWINSPMedian
NameLivaNova MedtronicBoston S.Abbott L.Edwards .Inspire . 
Mkt Cap5.0128.061.0179.258.71.659.9
P/S3.33.42.93.78.81.83.4
P/Op Inc30.917.914.127.030.5101.128.8
P/EBIT33.017.515.123.737.252.028.3
P/E25.524.517.438.157.515.825.0
P/CFO21.115.914.420.234.211.818.1
Total Yield3.9%6.9%5.8%5.1%1.7%6.3%5.4%
Dividend Yield0.0%2.9%0.0%2.4%0.0%0.0%0.0%
FCF Yield 3Y Avg4.5%5.3%2.1%3.4%2.0%3.3%3.4%
D/E0.10.20.20.20.00.00.1
Net D/E-0.00.20.20.1-0.1-0.20.1

Returns

LIVNMDTBSXABTEWINSPMedian
NameLivaNova MedtronicBoston S.Abbott L.Edwards .Inspire . 
1M Rtn15.9%7.5%-5.3%2.8%15.2%-22.5%5.1%
3M Rtn15.5%8.0%-16.4%-10.9%13.4%-11.6%-1.4%
6M Rtn23.2%29.4%-27.1%19.8%18.7%25.7%21.5%
12M Rtn70.2%4.0%-56.4%-14.6%21.1%-33.8%-5.3%
3Y Rtn109.2%40.3%-23.8%8.0%52.1%-60.1%24.2%
1M Excs Rtn15.1%6.8%-5.2%4.0%16.3%-20.9%5.4%
3M Excs Rtn19.3%11.6%-10.9%-7.8%15.6%-7.3%2.2%
6M Excs Rtn23.9%30.2%-26.3%20.5%19.5%26.4%22.2%
12M Excs Rtn57.0%-8.7%-68.3%-27.8%6.8%-45.6%-18.2%
3Y Excs Rtn24.1%-15.7%-86.7%-52.6%-12.7%-126.9%-34.2%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Cardiopulmonary785684604514483
Neuromodulation593554520477456
Other revenue1016303141
Advanced Circulatory Support    55
Total1,3881,2531,1541,0221,035


Operating Income by Segment
$ Mil20252024202320222021
Neuromodulation215195153173169
Cardiopulmonary108772617-6
Other expense-124-143-248-267-166
Advanced Circulatory Support    2
Total199129-68-77-1


Assets by Segment
$ Mil20252024202320222021
Cardiopulmonary1,045901962874921
Other assets921965   
Neuromodulation640641647647646
Advanced Circulatory Support  10121232
Other revenue  810653401
Total2,6062,5062,4302,2952,201


Price Behavior

null
LIVN Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta0.310.280.880.710.960.92
Up Beta-0.24-1.040.360.861.160.83
Down Beta0.860.420.210.480.590.83
Up Capture41%39%114%101%131%97%
Bmk +ve Days12182862130427
Stock +ve Days11203468129373
Down Capture-10%46%126%47%87%102%
Bmk -ve Days10253664121325
Stock -ve Days11222956119373

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with LIVN
LIVN68.6%39.2%1.40-
Sector ETF (XLV)18.4%17.1%0.8038.2%
Equity (SPY)5.2%14.4%0.1137.1%
Gold (GLD)-13.9%29.3%-0.5215.9%
Commodities (DBC)28.2%21.5%1.05-36.3%
Real Estate (VNQ)8.6%14.3%0.3339.1%
Bitcoin (BTCUSD)-35.8%43.9%-0.8911.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with LIVN
LIVN0.1%39.9%0.10-
Sector ETF (XLV)7.5%15.4%0.2937.4%
Equity (SPY)9.6%17.4%0.3940.3%
Gold (GLD)13.1%19.3%0.536.8%
Commodities (DBC)6.6%19.6%0.22-4.2%
Real Estate (VNQ)0.5%19.0%-0.0839.6%
Bitcoin (BTCUSD)-1.7%51.5%0.1520.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with LIVN
LIVN8.0%40.5%0.32-
Sector ETF (XLV)11.4%16.8%0.5542.4%
Equity (SPY)14.1%18.1%0.6645.8%
Gold (GLD)10.4%16.6%0.503.7%
Commodities (DBC)7.2%18.2%0.319.1%
Real Estate (VNQ)5.9%20.7%0.2443.7%
Bitcoin (BTCUSD)55.4%66.3%0.9512.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity6.4 Mil
Short Interest: % Change Since 101520262.6%
Average Daily Volume0.5 Mil
Days-to-Cover Short Interest12.4 days
Basic Shares Quantity55.1 Mil
Short % of Basic Shares11.5%

Earnings Returns History

Updated 11/13/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/4/202617.9%14.1% 
8/5/2026-8.4%-7.9%-3.4%
5/6/202615.1%24.6%28.0%
2/25/20261.8%-0.9%-8.3%
11/5/2025-5.8%-2.3%17.5%
8/6/202511.1%18.8%36.5%
5/7/202523.7%25.3%27.6%
2/25/2025-15.8%-15.7%-19.4%
...
SUMMARY STATS   
# Positive161311
# Negative81112
Median Positive6.4%9.3%9.1%
Median Negative-4.8%-6.2%-6.5%
Max Positive23.7%25.3%36.5%
Max Negative-15.8%-19.5%-20.4%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/4/202617.9%14.1% 
8/5/2026-8.4%-7.9%-3.4%
5/6/202615.1%24.6%28.0%
2/25/20261.8%-0.9%-8.3%
11/5/2025-5.8%-2.3%17.5%
8/6/202511.1%18.8%36.5%
5/7/202523.7%25.3%27.6%
2/25/2025-15.8%-15.7%-19.4%
10/30/2024-3.1%-6.2%-0.9%
7/31/2024-3.7%-10.7%-5.8%
5/1/202412.3%13.2%9.1%
2/21/20248.0%6.3%7.7%
11/1/20232.0%-3.2%-8.6%
7/26/20239.9%9.3%2.3%
5/3/20230.8%-0.8%-3.2%
2/22/2023-10.9%-13.3%-20.4%
11/2/20223.1%4.0%20.1%
8/3/2022-0.5%-3.6%-11.0%
5/4/2022-1.0%-19.5%-7.2%
2/23/20221.7%7.4%6.9%
11/3/202114.7%18.5%5.2%
7/28/20214.8%1.8%1.2%
4/28/20214.2%0.7%-0.7%
2/24/20210.5%2.9%-1.9%
SUMMARY STATS   
# Positive161311
# Negative81112
Median Positive6.4%9.3%9.1%
Median Negative-4.8%-6.2%-6.5%
Max Positive23.7%25.3%36.5%
Max Negative-15.8%-19.5%-20.4%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/04/202610-Q
06/30/202608/05/202610-Q
03/31/202605/06/202610-Q
12/31/202502/25/202610-K
09/30/202511/05/202510-Q
06/30/202508/06/202510-Q
03/31/202505/07/202510-Q
12/31/202402/25/202510-K
09/30/202410/31/202410-Q
06/30/202408/01/202410-Q
03/31/202405/03/202410-Q
12/31/202302/29/202410-K
09/30/202311/01/202310-Q
06/30/202307/26/202310-Q
03/31/202305/03/202310-Q
12/31/202202/27/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/04/202610-Q
06/30/202608/05/202610-Q
03/31/202605/06/202610-Q
12/31/202502/25/202610-K
09/30/202511/05/202510-Q
06/30/202508/06/202510-Q
03/31/202505/07/202510-Q
12/31/202402/25/202510-K
09/30/202410/31/202410-Q
06/30/202408/01/202410-Q
03/31/202405/03/202410-Q
12/31/202302/29/202410-K
09/30/202311/01/202310-Q
06/30/202307/26/202310-Q
03/31/202305/03/202310-Q
12/31/202202/27/202310-K
09/30/202211/02/202210-Q
06/30/202208/03/202210-Q
03/31/202205/04/202210-Q
12/31/202103/01/202210-K
09/30/202111/03/202110-Q
06/30/202107/28/202110-Q
03/31/202104/28/202110-Q
12/31/202003/01/202110-K
09/30/202010/29/202010-Q
06/30/202007/29/202010-Q
03/31/202004/30/202010-Q
12/31/201903/02/202010-K

Recent Forward Guidance

Updated 11/5/2026

Latest: Q3 2026 Earnings Reported 11/4/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Foreign Currency TailwindReported 0.01    
2026 Constant-Currency Revenue GrowthReported9.0%9.5%10.0% 1.0%RaisedGuidance: 8.5% for 2026
2026 Adjusted Diluted Earnings Per ShareReported4.44.454.52.3% RaisedGuidance: 4.35 for 2026
2026 Diluted Share CountReported 56.00 Mil    
2026 Adjusted Free Cash FlowReported140.00 Mil150.00 Mil160.00 Mil0.0% AffirmedGuidance: 150.00 Mil for 2026


Prior: Q2 2026 Earnings Reported 8/5/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Revenue GrowthReported8.0%8.5%9.0% 1.0%RaisedGuidance: 7.5% for 2026
2026 Adjusted Diluted EPSReported4.34.354.42.4% RaisedGuidance: 4.25 for 2026
2026 Adjusted Free Cash FlowReported140.00 Mil150.00 Mil160.00 Mil-11.8% LoweredGuidance: 170.00 Mil for 2026

Q1 2026 Earnings Reported 5/6/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Revenue GrowthReported7.0%7.5%8.0% 1.0%RaisedGuidance: 6.5% for 2026
2026 Adjusted Diluted EPSReported4.24.254.31.2% RaisedGuidance: 4.2 for 2026
2026 Adjusted Free Cash FlowReported160.00 Mil170.00 Mil180.00 Mil0 AffirmedGuidance: 170.00 Mil for 2026

Q4 2025 Earnings Reported 2/25/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Revenue GrowthReported6.0%6.5%7.0%-27.8%-2.5%Lower NewGuidance: 9.0% for 2025
2026 Adjusted Diluted EPSReported4.154.24.259.1% Higher NewGuidance: 3.85 for 2025
2026 Adjusted Free Cash FlowReported160.00 Mil170.00 Mil180.00 Mil0 Same NewGuidance: 170.00 Mil for 2025

Insider Activity

Updated 11/13/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Shvartsburg, AlexChief Financial OfficerDirectSell1113202690.912,500227,2753,831,584Form
2Bianchi, Francesco DirectSell914202678.013,500273,032345,893Form
3Story, Brooke DirectSell908202681.422,300187,270609,686Form
4Bianchi, Francesco DirectSell902202679.721,650131,538632,498Form
5Tezel, AhmetChief Innovation OfficerDirectSell813202677.742,675207,942473,409Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Shvartsburg, AlexChief Financial OfficerDirectSell1113202690.912,500227,2753,831,584Form
2Bianchi, Francesco DirectSell914202678.013,500273,032345,893Form
3Story, Brooke DirectSell908202681.422,300187,270609,686Form
4Bianchi, Francesco DirectSell902202679.721,650131,538632,498Form
5Tezel, AhmetChief Innovation OfficerDirectSell813202677.742,675207,942473,409Form
6Bianchi, Francesco DirectSell617202680.191,20096,228768,541Form
7Bianchi, Francesco DirectSell527202675.751,800136,350547,521Form
8Story, Brooke DirectSell1119202553.9425013,485336,154Form

Investor Activity (13F)

Updated Nov 22, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Paradice Investment Management LLC$26.5 Mil5.0%23TRIM -18.7%13F
Greenhouse Funds LLLP$48.8 Mil2.3%28ADD +538.4%13F
Redmile Group, LLC$6.9 Mil0.5%35TRIM -8.2%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Greenhouse Funds LLLP$48.8 Mil2.3%28ADD +538.4%13F
Active ManagerValue% of PortfolioTotal PositionsQoQAs OfFiling
Boone Capital Management LLC$17.8 Mil5.6%15ExitedDec 31, 202513F
Defilade Capital Management, L.P.$14.9 Mil2.0%33ExitedDec 31, 202513F
Paradice Investment Management LLC$26.5 Mil5.0%23TRIM -18.7%Mar 31, 202613F
Redmile Group, LLC$6.9 Mil0.5%35TRIM -8.2%Mar 31, 202613F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Greenhouse Funds LLLP$48.8 Mil2.3%28ADD +538.4%13F
Paradice Investment Management LLC$26.5 Mil5.0%23TRIM -18.7%13F
Redmile Group, LLC$6.9 Mil0.5%35TRIM -8.2%13F
Core Cache Last Updated: 11/21/2026